Terms: = Germ cell tumor AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Treatment
71 results:
1. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
[TBL] [Abstract] [Full Text] [Related]
2. Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment.
Higuchi F; Uzuka T; Matsuda H; Sumi T; Iwata K; Namatame T; Shin M; Akutsu H; Ueki K
Brain Tumor Pathol; 2024 Apr; 41(2):80-84. PubMed ID: 38294664
[TBL] [Abstract] [Full Text] [Related]
3. Glioma arising in the setting of mismatch repair deficiency-rare or are we missing it?
Goyal A; Rao S; Rishi KS; Ramaswamy V; Sadashiva N; Santosh V
Childs Nerv Syst; 2024 Jan; 40(1):233-237. PubMed ID: 37733272
[TBL] [Abstract] [Full Text] [Related]
4. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
[TBL] [Abstract] [Full Text] [Related]
5. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
[TBL] [Abstract] [Full Text] [Related]
6. Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.
Shinojima N; Ozono K; Yamamoto H; Abe S; Sasaki R; Tomita Y; Kai A; Mori R; Yamamoto T; Uekawa K; Matsui H; Nosaka K; Matsuzaki H; Komohara Y; Mikami Y; Mukasa A
Brain Tumor Pathol; 2023 Jul; 40(3):185-190. PubMed ID: 37086325
[TBL] [Abstract] [Full Text] [Related]
7. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
[TBL] [Abstract] [Full Text] [Related]
8. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
Kovács SA; Fekete JT; Győrffy B
Acta Pharmacol Sin; 2023 Sep; 44(9):1879-1889. PubMed ID: 37055532
[TBL] [Abstract] [Full Text] [Related]
9. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Tancredi A; Gusyatiner O; Bady P; Buri MC; Lomazzi R; Chiesi D; Messerer M; Hegi ME
Cell Death Dis; 2022 Dec; 13(12):1037. PubMed ID: 36513631
[TBL] [Abstract] [Full Text] [Related]
10. Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia: A Report of 14 Cases.
Ordulu Z; Mino-Kenudson M; Young RH; Van de Vijver K; Zannoni GF; Félix A; Burandt E; Wong A; Nardi V; Oliva E
Am J Surg Pathol; 2022 Dec; 46(12):1670-1681. PubMed ID: 36069807
[TBL] [Abstract] [Full Text] [Related]
11. Mismatch repair deficiency and MUTYH variants in small intestine-neuroendocrine tumors.
Helderman NC; Elsayed FA; van Wezel T; Terlouw D; Langers AMJ; van Egmond D; Kilinç G; Hristova H; Farina Sarasqueta A; Morreau H; Nielsen M; Suerink M;
Hum Pathol; 2022 Jul; 125():11-17. PubMed ID: 35417733
[TBL] [Abstract] [Full Text] [Related]
12. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
Ganesa S; Sule A; Sundaram RK; Bindra RS
Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070
[TBL] [Abstract] [Full Text] [Related]
13. SLC7A11 negatively associates with mismatch repair gene expression and endows glioblastoma cells sensitive to radiation under low glucose conditions.
Hu N; Hu WH; Zhou SL; Yang Z; Liang WL; Yang RY; Li MH; Jing Z; Li ZA; Fu XD; Wang XJ
Neoplasma; 2021 Nov; 68(6):1147-1156. PubMed ID: 34427100
[TBL] [Abstract] [Full Text] [Related]
14. Immunohistochemical screening for mismatch repair protein deficiency in paediatric high-grade gliomas - institutional experience and review of literature.
Alphones S; Chatterjee U; Singh A; Das A; Zameer L; Achari R; Bhattacharya A; Roy P
Childs Nerv Syst; 2021 Aug; 37(8):2521-2530. PubMed ID: 34097097
[TBL] [Abstract] [Full Text] [Related]
15. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the msh6 germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract] [Full Text] [Related]
16. Constitutional mismatch repair deficiency (CMMRD) presenting with high-grade glioma, multiple developmental venous anomalies and malformations of cortical development-a multidisciplinary/multicentre approach and neuroimaging clues to clinching the diagnosis.
Chhabda S; Sudhakar S; Mankad K; Jorgensen M; Carceller F; Jacques TS; Merve A; Aizpurua M; Chalker J; Garimberti E; D'Arco F
Childs Nerv Syst; 2021 Jul; 37(7):2375-2379. PubMed ID: 33247381
[TBL] [Abstract] [Full Text] [Related]
17. Pathological Findings of the Host Immune Reaction in the tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms.
Hasegawa S; Kobayashi N; Okubo N; Tokuhisa M; Goto A; Kurita Y; Sato T; Hosono K; Endo I; Nakajima A; Ichikawa Y
Intern Med; 2021 Apr; 60(7):977-983. PubMed ID: 33162477
[TBL] [Abstract] [Full Text] [Related]
18. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract] [Full Text] [Related]
19. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
Carroll MR; Ramalingam P; Salvo G; Fujimoto J; Solis Soto LM; Phoolcharoen N; Hillman RT; Cardnell R; Byers L; Frumovitz M
Int J Gynecol Cancer; 2020 Sep; 30(9):1303-1307. PubMed ID: 32727929
[TBL] [Abstract] [Full Text] [Related]
20. PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
Yuan AL; Meode M; Tan M; Maxwell L; Bering EA; Pedersen H; Willms J; Liao J; Black S; Cairncross JG; Blough MD
J Neurooncol; 2020 Jul; 148(3):463-472. PubMed ID: 32562246
[TBL] [Abstract] [Full Text] [Related]
[Next]